Product Description

4-FMA Capsules 130mg

4-FMA Capsules 130mg (4-Fluoromethamphetamine) Capsules 130mg is a synthetic stimulant and novel psychoactive substance (NPS) belonging to the substituted amphetamine class. It is the N-methylated analog of 4-fluoroamphetamine (4-FA) and a fluorinated derivative of methamphetamine. It has no approved medical uses and is sold primarily as a research chemical or designer drug, often in capsule or powder form.

Pharmacology and Mechanism of Action

4-FMA acts as a monoamine releasing agent and reuptake inhibitor, primarily affecting dopamine, norepinephrine, and serotonin. It has a more serotonergic profile compared to methamphetamine, contributing to its reported entactogenic (empathogenic) effects alongside classic stimulant properties.

It is also a CYP450 inhibitor, which can interact with other substances (e.g., increasing potency and toxicity of methamphetamine by slowing its metabolism). Limited in vitro data suggest it influences monoamine transporters, though detailed human receptor binding studies are scarce compared to 4-FA.

Pharmacokinetics: Onset is typically 20–40 minutes when taken orally, with peak effects around 2–5 hours and total duration of 4–8 hours (plus after-effects). A 130mg dose falls into the strong/heavy range according to user-sourced dosage charts.

Subjective Effects

At lower doses, users report stimulant effects: increased energy, focus, wakefulness, and euphoria. At higher doses (e.g., around 100–130mg), more entactogenic qualities may emerge, such as enhanced empathy, mood elevation, and sociability, somewhat resembling a milder MDMA-like experience mixed with amphetamine stimulation. Common side effects during use include jaw clenching, increased heart rate, sweating, and appetite suppression.

Safety Profile

Very limited human data exist, and 4-FMA carries significant risks. In vitro studies (primarily on primary rat hepatocytes) demonstrate hepatotoxicity (liver cell damage), with involvement of cytochrome P450 enzymes (CYP2E1, CYP3A4, CYP2D6) in its metabolism. It can destabilize mitochondrial membrane potential, reduce ATP, increase reactive oxygen/nitrogen species, and trigger apoptosis/necrosis pathways. Metabolism appears to play a complex role — some pathways may detoxify while others toxify the compound.

Cardiovascular risks are a major concern with fluorinated amphetamines. Related compounds like 4-FA are linked to hypertension, tachycardia, hyperthermia, headaches, and severe events such as cerebral hemorrhage or cardiomyopathy. Similar risks are expected with 4-FMA, especially at higher doses like 130mg.

Other risks:

• Neurotoxicity and potential serotonergic damage (inferred from structural analogs).
• Dependence and abuse potential.
• Overheating, dehydration, and serotonin syndrome (especially when combined with other serotonergic drugs).
• Unpredictable potency and purity in unregulated products.

Long-term effects are unknown but could include cardiovascular strain, liver issues, and mental health impacts.

Legal status (as of 2026): Varies by country. It is controlled in places like Australia (Schedule 9), Canada, China, and several European nations. In the US, it remains unscheduled federally but may fall under analog laws if intended for human consumption. Always check current local regulations.

Bottom line: 4-FMA produces stimulant and entactogenic effects via monoamine release, but with sparse safety data and demonstrated cellular toxicity (especially hepatic). A 130mg capsule represents a high dose with elevated risks of acute cardiovascular, hyperthermic, and organ toxicity. This information is for educational and scientific purposes only and does not encourage use. These substances are not equivalent to approved medications and carry substantial legal and health risks. Consult peer-reviewed sources and healthcare professionals for any related concerns. Harm reduction practices (testing, lower dosing, monitoring vitals) are essential if any use occurs despite the risks.

Additional Information